Disruption of virus-host cell interactions and cell signaling pathways as an anti-viral approach against influenza virus infections
暂无分享,去创建一个
[1] Daniel Becker,et al. Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication , 2010, Nature.
[2] A. García-Sastre,et al. PB1-F2 Expression by the 2009 Pandemic H1N1 Influenza Virus Has Minimal Impact on Virulence in Animal Models , 2010, Journal of Virology.
[3] Thorsten Wolff,et al. MEK inhibition impairs influenza B virus propagation without emergence of resistant variants , 2004, FEBS letters.
[4] K. Nichol,et al. The effectiveness of vaccination against influenza in healthy, working adults. , 1995, The New England journal of medicine.
[5] S. Pleschka,et al. Influenza-virus-induced signaling cascades: targets for antiviral therapy? , 2003, Trends in molecular medicine.
[6] J. Jansen,et al. Cistus incanus (CYSTUS052) for treating patients with infection of the upper respiratory tract. A prospective, randomised, placebo-controlled clinical study. , 2009, Antiviral research.
[7] Y. Lazebnik,et al. Caspases: enemies within. , 1998, Science.
[8] H. Pahl,et al. Activators and target genes of Rel/NF-kappaB transcription factors. , 1999, Oncogene.
[9] F. Hayden,et al. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. , 1992, Current topics in microbiology and immunology.
[10] S. Apers,et al. Proanthocyanidins in health care: current and new trends. , 2004, Current medicinal chemistry.
[11] J. Serkedjieva,et al. Antioxidant and prooxidant properties of a polyphenol‐rich extract from Geranium sanguineum L. in vitro and in vivo , 2008, Phytotherapy research : PTR.
[12] Thorsten Wolff,et al. Acetylsalicylic acid (ASA) blocks influenza virus propagation via its NF‐κB‐inhibiting activity , 2007, Cellular microbiology.
[13] New Millennium Antivirals against Pandemic and Epidemic Influenza: The Neuraminidase Inhibitors , 2002, Antiviral chemistry & chemotherapy.
[14] L. Aschenbrenner,et al. Sialidase-based anti-influenza virus therapy protects against secondary pneumococcal infection. , 2010, The Journal of infectious diseases.
[15] H. Klenk,et al. Proteolytic activation of the influenza virus hemagglutinin: The structure of the cleavage site and the enzymes involved in cleavage. , 1981, Virology.
[16] E. De Clercq,et al. Avian influenza A (H5N1) infection: targets and strategies for chemotherapeutic intervention , 2007, Trends in Pharmacological Sciences.
[17] R. König,et al. Human Host Factors Required for Influenza Virus Replication , 2010, Nature.
[18] Yoshihiro Kawaoka,et al. oseltamivir: descriptive study , 2022 .
[19] S. Ludwig. Exploited defense: how influenza viruses take advantage of antiviral signaling responses , 2007 .
[20] C. Widmann,et al. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. , 1999, Physiological reviews.
[21] Kazuhiro Iwai,et al. Linear ubiquitin assembly complex negatively regulates RIG-I- and TRIM25-mediated type I interferon induction. , 2011, Molecular cell.
[22] L. Staudt,et al. Active NF-kappaB signalling is a prerequisite for influenza virus infection. , 2004, The Journal of general virology.
[23] L. Nencioni,et al. Inhibition of influenza A virus replication by resveratrol. , 2005, The Journal of infectious diseases.
[24] L. Aschenbrenner,et al. DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. , 2007, The Journal of infectious diseases.
[25] F. Hayden,et al. Sialidase Fusion Protein as a Novel Broad-Spectrum Inhibitor of Influenza Virus Infection , 2006, Antimicrobial Agents and Chemotherapy.
[26] H. Klenk,et al. Proteolytic Activation of Influenza Viruses by Serine Proteases TMPRSS2 and HAT from Human Airway Epithelium , 2006, Journal of Virology.
[27] Frederick Hayden,et al. Developing new antiviral agents for influenza treatment: what does the future hold? , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[28] Stephan Ludwig,et al. Lung-specific expression of active Raf kinase results in increased mortality of influenza A virus-infected mice , 2004, Oncogene.
[29] Ronald Frank,et al. Peptide-Mediated Interference with Influenza A Virus Polymerase , 2007, Journal of Virology.
[30] Alan R. Saltiel,et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo , 1999, Nature Medicine.
[31] B. G. Hale,et al. The multifunctional NS1 protein of influenza A viruses. , 2008, The Journal of general virology.
[32] Ralph S. Baric,et al. Novel Influenza Virus NS1 Antagonists Block Replication and Restore Innate Immune Function , 2008, Journal of Virology.
[33] J. Ortín,et al. Development of an HTS Assay for the Search of Anti-influenza Agents Targeting the Interaction of Viral RNA with the NS1 Protein , 2008, Journal of biomolecular screening.
[34] J. Villard,et al. Antibacterial and antifungal activities of Cistus incanus and C. monspeliensis leaf extracts. , 1999, Therapie.
[35] G. Tannock,et al. Antiviral chemotherapeutic agents against respiratory viruses: where are we now and what’s in the pipeline? , 2004, Current opinion in pulmonary medicine.
[36] H. Radtke,et al. Effect of CYSTUS052® and green tea on subjective symptoms in patients with infection of the upper respiratory tract , 2010, Phytotherapy research : PTR.
[37] Stephan Ludwig,et al. The proapoptotic influenza A virus protein PB1‐F2 regulates viral polymerase activity by interaction with the PB1 protein , 2008, Cellular microbiology.
[38] J. Oxford,et al. In Vivo Prophylactic Activity of QR-435 Against H3N2 Influenza Virus Infection , 2007, American journal of therapeutics.
[39] Thorsten Wolff,et al. Ringing the alarm bells: signalling and apoptosis in influenza virus infected cells , 2006, Cellular microbiology.
[40] K. Thorlund,et al. Systematic review of influenza resistance to the neuraminidase inhibitors , 2011, BMC infectious diseases.
[41] H. Mario Geysen,et al. Novel inhibitor of influenza non-structural protein 1 blocks multi-cycle replication in an RNase L-dependent manner , 2011, The Journal of general virology.
[42] Isao Kouno,et al. Antibacterial spectrum of plant polyphenols and extracts depending upon hydroxyphenyl structure. , 2006, Biological & pharmaceutical bulletin.
[43] R. Gaynor,et al. The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β , 1998, Nature.
[44] S. Pleschka,et al. Caspase 3 activation is essential for efficient influenza virus propagation , 2003, The EMBO journal.
[45] R. Frank,et al. Identification of a PA-Binding Peptide with Inhibitory Activity against Influenza A and B Virus Replication , 2009, PloS one.
[46] R. Lamb,et al. Controlling influenza virus replication by inhibiting its proton channel. , 2007, Molecular bioSystems.
[47] H. Narita,et al. In Vitro and In Vivo Activities of Anti-Influenza Virus Compound T-705 , 2002, Antimicrobial Agents and Chemotherapy.
[48] V. Shahin,et al. Apoptosis leads to a degradation of vital components of active nuclear transport and a dissociation of the nuclear lamina , 2008, Proceedings of the National Academy of Sciences.
[49] H. Klenk,et al. Membrane Accumulation of Influenza A Virus Hemagglutinin Triggers Nuclear Export of the Viral Genome via Protein Kinase Cα-mediated Activation of ERK Signaling* , 2006, Journal of Biological Chemistry.
[50] E. Turpin,et al. Inhibition of Influenza Virus Infection by a Novel Antiviral Peptide That Targets Viral Attachment to Cells , 2006, Journal of Virology.
[51] T. Deng,et al. Hsp90 inhibitors reduce influenza virus replication in cell culture. , 2008, Virology.
[52] M. Newton,et al. Drosophila RNAi screen identifies host genes important for influenza virus replication , 2008, Nature.
[53] Virginia Korte,et al. A polyphenol rich plant extract, CYSTUS052, exerts anti influenza virus activity in cell culture without toxic side effects or the tendency to induce viral resistance. , 2007, Antiviral research.
[54] A. Lackenby,et al. The potential impact of neuraminidase inhibitor resistant influenza , 2008, Current opinion in infectious diseases.
[55] Hua-Yew Cheng,et al. Antiviral Properties of Prodelphinidin B-2 3′-O-Gallate from Green Tea Leaf , 2002, Antiviral chemistry & chemotherapy.
[56] H. Ly,et al. NF-κB Signaling Differentially Regulates Influenza Virus RNA Synthesis , 2008, Journal of Virology.
[57] Yu-Ling Huang,et al. (+)-Vitisin A inhibits influenza A virus-induced RANTES production in A549 alveolar epithelial cells through interference with Akt and STAT1 phosphorylation. , 2008, Planta medica.
[58] E. Haslam. Natural polyphenols (vegetable tannins) as drugs: possible modes of action. , 1996, Journal of natural products.
[59] Laurent Kaiser,et al. Influenza virus neuraminidase inhibitors , 2000, The Lancet.
[60] R. Lamb,et al. Orthomyxoviridae: The Viruses and Their Replication. , 1996 .
[61] P. Cohen. Protein kinases — the major drug targets of the twenty-first century? , 2002, Nature reviews. Drug discovery.
[62] S. Pleschka,et al. NF-κB-dependent Induction of Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) and Fas/FasL Is Crucial for Efficient Influenza Virus Propagation* , 2004, Journal of Biological Chemistry.
[63] Irene Ramos,et al. The Influenza Virus Protein PB1-F2 Inhibits the Induction of Type I Interferon at the Level of the MAVS Adaptor Protein , 2011, PLoS pathogens.
[64] F. Aoki,et al. Influenza Virus Susceptibility and Resistance to Oseltamivir , 2005, Antiviral therapy.
[65] Johannes G. Bode,et al. Influenza A Virus Inhibits Type I IFN Signaling via NF-κB-Dependent Induction of SOCS-3 Expression , 2008, PLoS pathogens.
[66] S. Pleschka,et al. MEK-Specific Inhibitor U0126 Blocks Spread of Borna Disease Virus in Cultured Cells , 2001, Journal of Virology.
[67] Rong Wang,et al. Influenza Virus PB1-F2 Protein Induces Cell Death through Mitochondrial ANT3 and VDAC1 , 2005, PLoS pathogens.
[68] Y. Lazebnik,et al. Caspases Disrupt the Nuclear-Cytoplasmic Barrier , 2000, The Journal of cell biology.
[69] D. Viemann,et al. H5N1 Virus Activates Signaling Pathways in Human Endothelial Cells Resulting in a Specific Imbalanced Inflammatory Response , 2011, The Journal of Immunology.
[70] Rei-Lin Kuo,et al. The CPSF30 Binding Site on the NS1A Protein of Influenza A Virus Is a Potential Antiviral Target , 2006, Journal of Virology.
[71] C. Lam,et al. The use of an herbal formula by hospital care workers during the severe acute respiratory syndrome epidemic in Hong Kong to prevent severe acute respiratory syndrome transmission, relieve influenza-related symptoms, and improve quality of life: a prospective cohort study. , 2005, Journal of alternative and complementary medicine.
[72] S. Pleschka,et al. Inhibitory activity of a standardized elderberry liquid extract against clinically-relevant human respiratory bacterial pathogens and influenza A and B viruses , 2011, BMC complementary and alternative medicine.
[73] O. Planz,et al. Influenza viruses and the NF-κB signaling pathway – towards a novel concept of antiviral therapy , 2008, Biological chemistry.
[74] R. Lamb,et al. The M2 Proton Channels of Influenza A and B Viruses* , 2006, Journal of Biological Chemistry.
[75] J. Oxford,et al. Preclinical In Vitro Activity of QR-435 Against Influenza A Virus as a Virucide and in Paper Masks for Prevention of Viral Transmission , 2007, American journal of therapeutics.
[76] C. Ehrhardt,et al. A new player in a deadly game: influenza viruses and the PI3K/Akt signalling pathway , 2009, Cellular microbiology.
[77] Y. Henis,et al. Clustering of Raft-Associated Proteins in the External Membrane Leaflet Modulates Internal Leaflet H-Ras Diffusion and Signaling , 2006, Molecular and Cellular Biology.
[78] T. Shimamura,et al. Inhibition of the infectivity of influenza virus by tea polyphenols. , 1993, Antiviral research.
[79] A. Nahrstedt,et al. Proanthocyanidins from Cistus incanus , 1993 .
[80] N. Bovin,et al. Multimeric glycotherapeutics: New paradigm , 2004, Glycoconjugate Journal.
[81] S. Inoue,et al. Influenza A virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I. , 2009, Cell host & microbe.
[82] J. Tomassini,et al. A novel antiviral agent which inhibits the endonuclease of influenza viruses , 1996, Antimicrobial agents and chemotherapy.
[83] N. Hacohen,et al. A Physical and Regulatory Map of Host-Influenza Interactions Reveals Pathways in H1N1 Infection , 2009, Cell.
[84] J. Serkedjieva,et al. Protective efficacy of an aerosol preparation, obtained from Geranium sanguineum L., in experimental influenza infection. , 2008, Pharmazie.
[85] A. Scalbert. Antimicrobial properties of tannins , 1991 .
[86] D. Viemann,et al. Essential Impact of NF-κB Signaling on the H5N1 Influenza A Virus-Induced Transcriptome1 , 2009, The Journal of Immunology.
[87] Stephan Ludwig,et al. Antiviral activity of the MEK-inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo. , 2011, Antiviral research.
[88] Julie L. McAuley,et al. The Effects of Influenza A Virus PB1-F2 Protein on Polymerase Activity Are Strain Specific and Do Not Impact Pathogenesis , 2009, Journal of Virology.
[89] T. Wolff,et al. CRK adaptor protein expression is required for efficient replication of avian influenza A viruses and controls JNK‐mediated apoptotic responses , 2010, Cellular microbiology.
[90] C. Ehrhardt,et al. CYSTUS052, a polyphenol-rich plant extract, exerts anti-influenza virus activity in mice. , 2007, Antiviral research.
[91] S. Pleschka,et al. Inhibition of influenza virus-induced NF-kappaB and Raf/MEK/ERK activation can reduce both virus titers and cytokine expression simultaneously in vitro and in vivo. , 2011, Antiviral research.
[92] R. Gaynor,et al. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. , 1998, Nature.
[93] S. Ludwig. Influenza viruses and MAP kinase cascades – Novel targets for an antiviral intervention? , 2007 .
[94] M. D. de Jong,et al. Neuraminidase Inhibitors and their Role in Avian and Pandemic Influenza , 2005, Antiviral therapy.
[95] M. Karin,et al. JNK2 and IKKbeta are required for activating the innate response to viral infection. , 1999, Immunity.
[96] A. Nahrstedt,et al. Flavan-3-ols and proanthocyanidins from Cistus incanus , 1991 .
[97] David J. Adams,et al. The IFITM Proteins Mediate Cellular Resistance to Influenza A H1N1 Virus, West Nile Virus, and Dengue Virus , 2009, Cell.
[98] N. Cox,et al. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. , 2006, JAMA.
[99] R. Wagner,et al. Avian and 1918 Spanish Influenza A Virus NS1 Proteins Bind to Crk/CrkL Src Homology 3 Domains to Activate Host Cell Signaling* , 2008, Journal of Biological Chemistry.
[100] Liliana Jiménez,et al. Polyphenols: food sources and bioavailability. , 2004, The American journal of clinical nutrition.
[101] Masato Kubo,et al. Suppressors of cytokine signaling and immunity , 2003, Nature Immunology.
[102] R. Frank,et al. Disruption of the Viral Polymerase Complex Assembly as a Novel Approach to Attenuate Influenza A Virus* , 2010, The Journal of Biological Chemistry.
[103] Thorsten Wolff,et al. Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade , 2001, Nature Cell Biology.
[104] B. Seong,et al. Antiviral effect of catechins in green tea on influenza virus. , 2005, Antiviral research.
[105] M. Peiris. Pathogenesis of avian flu H5N1 and SARS. , 2006, Novartis Foundation symposium.
[106] P. Palese,et al. Influenza A virus PB1-F2: a small protein with a big punch. , 2007, Cell host & microbe.